Drugs / LY3499446
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04165031 | Nov 2019 → Oct 2020 | colorectal cancer, non-small cell lung carcinoma | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3499446 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04165031 ↗ |
| Modality | Small molecule | — CHEMBL5095252 ↗ |
| Route | Oral | “Administered orally” NCT04165031 ↗ |